Edwards Lifesciences Corp（EW）财务数据EWEdwards Lifesciences Corp

Edwards Lifesciences Corporation (EW) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Transcatheter Aortic Valve Replacement, accounting for 72.6% of total sales, equivalent to $1.20B. Other significant revenue streams include Surgical Heart Valve Therapy and Transcatheter Mitral and Tricuspid Therapies. Understanding this composition is critical for investors evaluating how EW navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Edwards Lifesciences Corporation maintains a gross margin of 77.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.84%, while the net margin is 13.87%. These profitability ratios, combined with a Return on Equity (ROE) of 9.26%, provide a clear picture of how effectively EW converts its operational activities into shareholder value.

In the context of the broader market, EW competes directly with industry leaders such as BDX and MDLN. With a market capitalization of $51.85B, it holds a leading position in the sector. When comparing efficiency, EW's gross margin of 77.46% stands against BDX's 46.76% and MDLN's 26.52%. Such benchmarking helps identify whether Edwards Lifesciences Corporation is trading at a premium or discount relative to its financial performance.

The company has shown strong revenue growth, with Q2 2026 revenue reported at $1.74 billion, up from $1.65 billion in Q1 2026. The gross margin remains robust at 77.46%, indicating efficient cost management.